



**P.O. Box 342
Minneapolis, MN 55440-0342
612-863-4678**

**2023
Allina Regional Hospitals
Antimicrobial Susceptibilities
of Major Pathogens**

- The intent of this document is to provide a preliminary guide to susceptibilities. This information should be used together with the specific susceptibility results of the isolated organism and guidelines from current publications. This report summarizes routinely tested antibiotics. Actual patient reports may selectively exclude some results.
- Results are from inpatients only and include only one isolate per patient.
- Isolates collected from Emergency Department visits are included in the inpatient antibiogram.
- MRSA and VRE surveillance culture isolates are not included.
- All intermediate (I) interpretations are included in the resistant category.
- All organisms identified are held for a period of 7 days after the final results have been reported in case further testing is requested. Blood culture isolates are held for 1 month. Testing of additional antimicrobials is available upon request.
- Additional guidance can be found on the [Allina Health Antibiotic Stewardship Program](#) web page.

For further information, contact:

Brenda Katz, MD, Pathologist,
Brenda.Katz@allina.com, 612-863-4708

REGIONAL HOSPITALS -2023 ANTIMICROBIAL SUSCEPTIBILITIES

GRAM NEGATIVE BACILLI	ISOLATES	Antibiotics													
		AMPICILLIN	AMPIOILLIN/SULBACTAM	CEFAZOLIN-UC *	CEFEPIME	CEFTAZIDIME	CEFTRIAXONE	GENTAMICIN	LEVOFLOXACIN	MEROPENEM	NITROFURANTOIN ^U	PIPERACILLIN/TAZO	TOBRAMYCIN	TRIMETHOPRIM/SULFA	
<i>Acinetobacter</i> species (all combined)	30		100		100	76	100	100	100	100	100		65	93	96
<i>Citrobacter</i> species (all combined)	180				100	91	91	95	97	91	100	90	91	97	90
<i>Enterobacter</i> species (all combined)	171				98	85	83	95	98	91	98	53	81	98	95
<i>Escherichia coli</i>	3445	61	70	92	95	95	94	82	94	78	99	98	96	94	82
<i>Klebsiella aerogenes</i> (formerly <i>Ent. aerogenes</i>)	78				100	87	87	100	100	100	100	33	88	100	100
<i>Klebsiella oxytoca</i>	138		64		96	96	96	98	98	98	99	90	92	98	97
<i>Klebsiella pneumoniae</i>	531		89	95	96	96	96	93	98	91	99	37	96	97	91
<i>Klebsiella variicola</i>	92		98		100	100	100	100	100	98	100	82	98	100	98
<i>Morganella morganii</i>	46		10		95	93	91	86	97	84	100		97	100	86
<i>Proteus mirabilis</i>	290	89	95	97	98	98	99	88	94	88	99		99	95	89
<i>Pseudomonas aeruginosa</i>	317				93	93		89	97	84	95		92	99	
<i>Serratia marcescens</i>	42				100	100	97	92	100	90	100			95	97

* Cefazolin; the % susceptible can only be ascertained on isolates of *E. coli*, *Klebsiella pneumoniae*, and *Proteus mirabilis* from uncomplicated UTIs. The cefazolin threshold for susceptible is <= 2 µg/ml for all other sources and Enterobacterales. The lowest dilution for cefazolin on the Allina FDA cleared automated platform is 4 µg/ml, thus no susceptible results can be determined by this method.

>90% Susceptible
61-89% Susceptible
0-60% Susceptible

GRAM POSITIVE COCCI	ISOLATES	Antibiotics																						
		AMPICILLIN	AZITHROMYCIN	CEFALOSPORINS	CEFTRIAXONE	CEFTRIAXONE-MENINGITIS ²	CEFTRIAXONE-NONMENINGITIS ³	CLARITHROMYCIN	CLINDAMYCIN	DAPTOMYCIN ⁴	DOXYCYCLINE	ERYTHROMYCIN	GENTAMICIN	LEVOFLOXACIN	LINEZOLID	NITROFURANTOIN ^U	OXACILLIN	PENICILLIN	PENICILLIN-IV-MENINGITIS ⁵	PENICILLIN-IV-NONMENINGITIS ⁵	RIFAMPIN ⁷	TRIMETHOPRIM/SULFA	VANCOMYCIN	
<i>Enterococcus faecalis</i>	679	99							70				87 ^U	100	99		98							99
<i>Enterococcus faecium</i> ¹	61	37							23				36 ^U	100	38		36							67
<i>Staphylococcus aureus</i>	817		73					81	100	97	58	99	79	100	100	73						99	93	100
<i>Staphylococcus Coag Negative</i>	176		60					60	100	93	41	94	71	100	98	60						98	76	100
<i>Staphylococcus lugdunensis</i>	77		96					83	100	100	83	100	100	100		96						100	100	100
<i>Strep. agalactiae</i> (Strep Group B)	75	100		100				45			39		97	100			100							100
<i>Strep. dysgalactiae</i>	47	100		100				82			82		100	100			100							100
<i>Strep. pneumoniae</i> **	56		71		94	100	71										81	100	81			85		100
<i>Strep. pyogenes</i> (Beta Strep Group A)	49	100		100				81			81		100	100			100							100

^u Reported on urine isolates only.

¹ Daptomycin does not have recognized breakpoints for *E. faecium*. Susceptibilities reported in this antibiogram are based on the susceptible dose dependent (SDD) MIC ≤ 4 $\mu\text{g/mL}$ using an 8-12 mg/kg daily regimen. Infectious Disease consultation is recommended prior to utilizing daptomycin to cover *E. faecium*.

² Ceftriaxone - IV meningitis susceptible MIC ≤ 0.5 $\mu\text{g/mL}$.

³ Ceftriaxone - IV non-meningitis susceptible MIC ≤ 1 $\mu\text{g/mL}$.

⁴ Daptomycin not reported on isolates from respiratory tract.

⁵ Gentamicin should not be used as monotherapy for gram positive infections.

⁶ Penicillin - Oral and IV meningitis susceptible MIC ≤ 0.06 $\mu\text{g/mL}$

⁷ Penicillin - IV nonmeningitis susceptible MIC ≤ 2 $\mu\text{g/mL}$.

⁸ Rifampin should not be used alone for antimicrobial therapy.

** *S.pneumoniae* isolate distribution by specimen type; 63% blood, 28% respiratory, 1.7% spinal fluid, 7% other specimen types.

Links to Related Content

[Allina Health Laboratory](#)

[Organism Groupings of Routinely Test Antimicrobials at Allina Health Laboratory](#)

[Allina Health Antimicrobial Susceptibility Data](#)

[2024 Allina Health Antimicrobial Costs](#)

[Pharmacy Services](#)

[Antimicrobial Stewardship](#)